GlassScriptPhysician profile
Mamta Chhetri
NPI 1679844641
$6,749.10
in general payments reported to CMS, 2019-2025
35 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $15.86 · 2021: $130 · 2022: $654 · 2023: $1,969 · 2024: $2,063 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,225.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,152.79 | 2019-2025 | Evenity, Prolia, Tepezza |
| Cequr Corporation | $919.80 | 2023-2025 | Cequr Simplicity |
| Novo Nordisk INC | $676.61 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $556.86 | 2021-2025 | Minimed 780g |
| Dexcom, INC. | $551.72 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $463.87 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $439.26 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Sanofi-Aventis U.S. LLC | $336.54 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.53 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $132.30 | 2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $128.27 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $120.85 | 2022-2025 | Omnipod |
| Ascendis Pharma Endocrinology INC | $117.71 | 2024-2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $112.49 | 2022-2023 | Farxiga |
| Radius Health, INC. | $84.61 | 2022-2023 | Tymlos |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $76.10 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $68.99 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Corcept Therapeutics | $66.41 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.14 | 2023 | Tradjenta, Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.50 | 2023 | Lifevest |
| Medtronic Minimed, INC. | $60.19 | 2019 | |
| Mannkind Corporation | $57.25 | 2023 | Afrezza |
| Alexion Pharmaceuticals, INC. | $42.27 | 2023-2025 | Strensiq |
| Amphastar Pharmaceuticals, INC. | $37.31 | 2024 | |
| Almatica Pharma LLC | $36.16 | 2024 | Teriparatide, Loreev Xr |
| Halozyme INC | $31.10 | 2023 | |
| Neurocrine Biosciences, INC. | $25.15 | 2025 | |
| Pfizer INC. | $24.48 | 2024 | |
| Eisai INC. | $24.33 | 2022 | |
| Nestle Healthcare Nutrition INC. | $22.71 | 2022 | |
| Madrigal Pharmaceuticals | $20.02 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $17.92 | 2024 | Xyosted |
| Recordati_rare_diseases_inc. | $17.49 | 2024 | Signifor Lar, Isturisa |
| Amneal Pharmaceuticals LLC | $14.88 | 2023 | Unithroid |
| Kyowa Kirin, INC. | $14.49 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamta Chhetri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.